How the Integration of START and CURC Is Advancing Cancer Research and Clinical Trials

ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research Center (now START Carolinas) is reshaping the landscape of genitourinary oncology research and clinical trial delivery. You can also follow this interview on LinkedIn using this link:>>>

Nick Slack shares strategic insights on expanding global access to early- and late-phase cancer trials, the development of patient-derived xenograft (PDX) models, and the creation of a robust translational pipeline. Learn how START is embedding cancer trials within urology practices, scaling radioligand therapy capabilities, and driving innovation to accelerate precision oncology breakthroughs.

Some of the main topics in this interview include:

• Could you provide an overview of the integration of the Carolina Urologic Research Center into The START Center for Cancer Research’s global network? How does START Carolinas, complement START’s overall vision for oncology research, and what was the strategic reasoning behind its acquisition?
• START Carolinas has conducted nearly 500 clinical trials in genitourinary oncology. How will its integration with the START network further enhance its ability to conduct clinical research?
• One of the unique features of START’s new dedicated Center of Excellence (COE) in urological cancers is its direct patient-to-Patient-Derived Xenograft translational service. Could you explain how this model will accelerate the transition from research findings to clinical applications?
• START Carolinas is known for its strong relationships with sponsors and industry partners. How do you plan to leverage these relationships to expand START’s global reach and effectiveness?
• Genitourinary cancers are rapidly increasing globally. What role do you see the Center of Excellence playing in addressing this growing healthcare challenge?
• How will START Carolinas influence the development of personalized medicine in urologic oncology?